Acadia Pharmaceuticals (ACAD) Leases (2019 - 2025)
Historic Leases for Acadia Pharmaceuticals (ACAD) over the last 7 years, with Q3 2025 value amounting to $49.7 million.
- Acadia Pharmaceuticals' Leases rose 1224.78% to $49.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.7 million, marking a year-over-year increase of 1224.78%. This contributed to the annual value of $46.6 million for FY2024, which is 1019.0% down from last year.
- Latest data reveals that Acadia Pharmaceuticals reported Leases of $49.7 million as of Q3 2025, which was up 1224.78% from $51.0 million recorded in Q2 2025.
- Acadia Pharmaceuticals' 5-year Leases high stood at $63.1 million for Q1 2021, and its period low was $44.3 million during Q3 2024.
- Over the past 5 years, Acadia Pharmaceuticals' median Leases value was $54.2 million (recorded in 2023), while the average stood at $54.1 million.
- Its Leases has fluctuated over the past 5 years, first surged by 67881.98% in 2021, then tumbled by 1281.57% in 2024.
- Over the past 5 years, Acadia Pharmaceuticals' Leases (Quarter) stood at $58.3 million in 2021, then decreased by 4.63% to $55.6 million in 2022, then dropped by 6.69% to $51.9 million in 2023, then dropped by 10.19% to $46.6 million in 2024, then increased by 6.66% to $49.7 million in 2025.
- Its last three reported values are $49.7 million in Q3 2025, $51.0 million for Q2 2025, and $50.6 million during Q1 2025.